Switching to Latanoprostene Bunod 0.024% in OAG and OHT patients


Study concluded that the short-term results of LBN to treat mild-to-modern OAG and OHT was safe and efficacious.

(Image Credit: AdobeStock/Julien Tromeur)

(Image Credit: AdobeStock/Julien Tromeur)

Reviewed by Constance O Okeke, MD, MSCE

Latanoprostene bunod 0.024% (LBN) (Vyzulta, Bausch & Lomb), a prostaglandin analog (PGA), received FDA approval in 2017 based on data obtained in 2 prospective randomized, clinical trials of 840 patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

First author Constance Okeke, MD, MSCE, and colleagues took those results a step further and evaluated the performance of LBN in a real-world clinical setting,1 which can differ substantially from that in randomized clinical trials. She is a glaucoma specialist at Virginia Eye Consultants and assistant professor of Ophthalmology at Eastern Virginia Medical School, Norfolk, VA.

All of the patients in this retrospective noninterventional multicenter chart review had mild-to-moderate OAG or OHT and were switched to LBN, at which time they were taking 1 or 2 intraocular pressure (IOP)-lowering drugs. The main study outcome was the change in IOP from the index visit to each of the next 2 follow-up visits. The investigators analyzed the overall data and 2 patient subgroups: those previously on a PGA with/without another IOP-lowering product (PGA-all) and those previously on a PGA alone (PGA-monotherapy), Okeke recounted.

The overall data from 49 patients were analyzed; the PGA-all subgroup was comprised of 41 patients and the PGA monotherapy subgroup 32 patients. The primary endpoint, the change in IOP, showed that there was roughly a 25% IOP decrease from the baseline visit to visit 1 and that decrease was sustained out to visit 2. The IOP decreases in the subgroups were similar to that found in the overall data, Okeke reported.

The study concluded that the short-term results of LBN to treat mild-to-modern OAG and OHT was safe and efficacious.

In commenting on the results, she explained that this short-term retrospective study provides physicians with a window into sustainability, ie, in this study the interval between 2 study visits. Okeke advised that future studies are needed to assess the drug’s effect over longer periods.

“The long-term clinical trials, APOLLO, LUNAR, and JUPITER,2-4 showed the consistent IOP-lowering ability of LBN, with rates of IOP reduction maintained up to 1 year. When these observations are combined with the short-term results, there is confidence regarding use in real-world clinical practice to determine how it works in a glaucoma population. These data may help inform clinicians on the potential effectiveness of LBN when switching patients with mild-to-moderate OAG/OHT from a previously administered PGA to LBN,” Okeke said.

LBN: more than just a switch drug: dual mechanism of action

Okeke considers LBN to be an extremely versatile treatment with a dual mechanism of action, which differs from other members of this drug class. PGAs affect the uveal-scleral pathway; in contrast, LBN, which is 1 molecule with 2 moieties, it also affects the uveoscleral pathway by increasing outflow, and it exerts another unique action of nitric oxide that increases outflow through the trabecular meshwork, she explained.

“This activity in both pathways is what makes its ability to lower IOP really robust,” she commented. Because of this, LBN can be considered as a treatment for all degrees of glaucoma not just advanced disease.

The beauty of the drug’s ability to work so well lies in the response of the trabecular meshwork. This pathway, with disease progression, becomes stiffer and less modifiable. “There is a strong therapeutic impact when the trabecular meshwork can be made to respond to therapy because of the nitric oxide component, which is why I believe that LBN has a very important role in the early stages of glaucoma,” she explained.

In her practice, she uses LBN as a first-line agent since it became commercially available.

In addition to patients with established diagnoses of glaucoma, she also prescribes it for treatment-naive eyes.5 “The patients did very well in that retrospective study. There was an IOP reduction of about 31% IOP, but the decrease was even more powerful in patients with elevated IOPs above 21 mmHg, with a mean reduction of 41% from baseline,” she reported.

She also mentioned that LBN seems to work better in early-stage glaucoma compared with severe disease. “This performance in early-stage disease plays into the drug’s mechanism of action. That is, the nitric oxide component is, I believe, is what causes the majority of the IOP-lowering ability. Other PGAs don’t have this strong mechanism of action that works on the trabecular meshwork.”

Constance O. Okeke, MD, MSCE
E: cokeke@cvphealth.com
Okeke is with Virginia Eye Consultants and assistant professor of Ophthalmology, Eastern Virginia Medical School, Norfolk, VA. She is a consultant to Bausch & Lomb.
  1. Okeke CO, Cothran NL, Brinkley DA, et al. Latanoprostene bunod 0.024% in patients with open-angle glaucoma switched from prior pharmacotherapy: a retrospective chart review. Clin Ophthalmol. 2024;18:18 409–422.
  2. Kaufman PL. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Expert Opin Pharmacother. 2017;18:433–444.
  3. Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL. Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma. 2018;27:7–15.
  4. Kawase K, Vittitow JL, Weinreb RN, Araie M, JUPITER Study Group Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER Study. Adv Ther. 2016;33(9):1612–1627.
  5. Okeke CO, Burstein ES, Trubnik V, et al. Retrospective chart review on real-world use of latanoprostene bunod 0.024% in treatment-naïve patients with open-angle glaucoma. Ophthalmol Ther. 2020;9:1041-53; DOI 10.1007/s40123-020-00307-0
Recent Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
© 2024 MJH Life Sciences

All rights reserved.